Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales

Moderna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales. The company forecasts lower-than-expected Q2 revenue but aims for a significant share of Europe's respiratory vaccine market with its mCombriax launch in 2027. Investors are now focused on the company's diversified pipeline beyond COVID-19.

Go to News Site